{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:42:56Z","timestamp":1793050976912,"version":"4.5.0"},"reference-count":175,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01518"],"award-info":[{"award-number":["PI19\/01518"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRIS against Cancer foundation","award":["grant 2018\/001"],"award-info":[{"award-number":["grant 2018\/001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The study of cell-free DNA (cfDNA) and other peripheral blood components (known as \u201cliquid biopsies\u201d) is promising, and has been investigated especially in solid tumors. Nevertheless, it is increasingly showing a greater utility in the diagnosis, prognosis, and response to treatment of hematological malignancies; in the future, it could prevent invasive techniques, such as bone marrow (BM) biopsies. Most of the studies about this topic have focused on B-cell lymphoid malignancies; some of them have shown that cfDNA can be used as a novel way for the diagnosis and minimal residual monitoring of B-cell lymphomas, using techniques such as next-generation sequencing (NGS). In myelodysplastic syndromes, multiple myeloma, or chronic lymphocytic leukemia, liquid biopsies may allow for an interesting genomic representation of the tumor clones affecting different lesions (spatial heterogeneity). In acute leukemias, it can be helpful in the monitoring of the early treatment response and the prediction of treatment failure. In chronic lymphocytic leukemia, the evaluation of cfDNA permits the definition of clonal evolution and drug resistance in real time. However, there are limitations, such as the difficulty in obtaining sufficient circulating tumor DNA for achieving a high sensitivity to assess the minimal residual disease, or the lack of standardization of the method, and clinical studies, to confirm its prognostic impact. This review focuses on the clinical applications of cfDNA on the minimal residual disease in hematological malignancies.<\/jats:p>","DOI":"10.3390\/cancers14051310","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T20:36:30Z","timestamp":1646339790000},"page":"1310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-886X","authenticated-orcid":false,"given":"Rafael","family":"Colmenares","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Imas12, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Imas12, 28041 Madrid, Spain"},{"name":"Hematological Malignancies Clinical Research Unit, CNIO, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Barrio","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Imas12, 28041 Madrid, Spain"},{"name":"Hematological Malignancies Clinical Research Unit, CNIO, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Imas12, 28041 Madrid, Spain"},{"name":"Hematological Malignancies Clinical Research Unit, CNIO, 28029 Madrid, Spain"},{"name":"Department of Medicine, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Imas12, 28041 Madrid, Spain"},{"name":"Hematological Malignancies Clinical Research Unit, CNIO, 28029 Madrid, Spain"},{"name":"Department of Medicine, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000499337","article-title":"Liquid Biopsy: General Concepts","volume":"63","author":"Poulet","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-med-062310-094219","article-title":"Circulating Tumor Cells and Circulating Tumor DNA","volume":"63","author":"Schwarzenbach","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating Liquid Biopsies into the Management of Cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.7150\/thno.18588","article-title":"Circulating Tumor Cells: Moving Biological Insights into Detection","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.ctrv.2020.102106","article-title":"Liquid Biopsy in Lymphoma: Molecular Methods and Clinical Applications","volume":"91","author":"Cirillo","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1002\/jcp.26481","article-title":"Exosomal MiRNAs as Novel Cancer Biomarkers: Challenges and Opportunities","volume":"233","author":"Salehi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1126\/science.328.5978.562","article-title":"Cell Biology. Beyond Clotting: The Powers of Platelets","volume":"328","author":"Leslie","year":"2010","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1182\/blood-2011-03-344408","article-title":"Blood Platelets Contain Tumor-Derived RNA Biomarkers","volume":"118","author":"Nilsson","year":"2011","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis","volume":"30","author":"Becker","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_10","first-page":"e89631","article-title":"Plasma Vesicle MiRNAs for Therapy Response Monitoring in Hodgkin Lymphoma Patients","volume":"1","author":"Zijlstra","year":"2016","journal-title":"JCI Insight"},{"key":"ref_11","first-page":"241","article-title":"Nuclear Acids In Human Blood Plasma","volume":"142","author":"Mandel","year":"1948","journal-title":"C. R. Seances Soc. Biol. Fil."},{"key":"ref_12","first-page":"646","article-title":"Free DNA in the Serum of Cancer Patients and the Effect of Therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000226740","article-title":"Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients","volume":"46","author":"Stroun","year":"1989","journal-title":"Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"FSO295","DOI":"10.4155\/fsoa-2017-0140","article-title":"Kinetics of Circulating Cell-Free DNA for Biomedical Applications: Critical Appraisal of the Literature","volume":"4","author":"Khier","year":"2018","journal-title":"Future Sci. OA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0009-8981(01)00665-9","article-title":"About the Possible Origin and Mechanism of Circulating DNA","volume":"313","author":"Stroun","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1373\/clinchem.2007.092734","article-title":"The Origin of Circulating Free DNA","volume":"53","author":"Pretorius","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1196\/annals.1448.022","article-title":"Circulating DNA. Its Origin and Fluctuation","volume":"1137","author":"Pretorius","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced Detection of Circulating Tumor DNA by Fragment Size Analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_19","first-page":"1659","article-title":"DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of Cell-Free DNA Analysis to Cancer Treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-Free Circulating DNA in Hodgkin\u2019s and Non-Hodgkin\u2019s Lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid Biopsies: Genotyping Circulating Tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute Quantification by Droplet Digital PCR versus Analog Real-Time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1586\/14737159.2015.1019476","article-title":"Potential Clinical Utility of Ultrasensitive Circulating Tumor DNA Detection with CAPP-Seq","volume":"15","author":"Bratman","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions\u2014A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2018.194712","article-title":"A Novel Deep Targeted Sequencing Method for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia","volume":"104","author":"Onecha","year":"2019","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3324\/haematol.2020.254623","article-title":"Monitoring of Clonal Evolution of Acute Myeloid Leukemia Identifies the Leukemia Subtype, Clinical Outcome and Potential New Drug Targets for Post-Remission Strategies or Relapse","volume":"106","author":"Onecha","year":"2021","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MOH.0000000000000464","article-title":"Next-Generation Sequencing-Based Minimal Residual Disease Monitoring in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome","volume":"25","author":"Shapiro","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/s41375-021-01265-7","article-title":"Current Challenges and Unmet Medical Needs in Myelodysplastic Syndromes","volume":"35","author":"Platzbecker","year":"2021","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Honor\u00e9, N., Galot, R., van Marcke, C., Limaye, N., and Machiels, J.-P. (2021). Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact. Cancers, 13.","DOI":"10.3390\/cancers13215364"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3343\/alm.2022.42.2.141","article-title":"Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing","volume":"42","author":"Shin","year":"2022","journal-title":"Ann. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_34","unstructured":"National Comprehensive Cancer Network (2022). Acute Myeloid Leukemia (Version 1.2022), National Comprehensive Cancer Network."},{"key":"ref_35","unstructured":"National Comprehensive Cancer Network (2022). Myelodysplastic Syndromes (Version 3.2022), National Comprehensive Cancer Network."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised Response Criteria for Polycythemia Vera and Essential Thrombocythemia: An ELN and IWG-MRT Consensus Project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) Consensus Report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"ref_38","unstructured":"National Comprehensive Cancer Network (2021). Myeloproliferative Neoplasms (Version 2.2021), National Comprehensive Cancer Network."},{"key":"ref_39","unstructured":"National Comprehensive Cancer Network (2022). Chronic Myeloid Leukemia (Version 2.2022), National Comprehensive Cancer Network."},{"key":"ref_40","unstructured":"National Comprehensive Cancer Network (2021). Acute Lymphoblastic Leukemia (Version 4.2021), National Comprehensive Cancer Network."},{"key":"ref_41","unstructured":"National Comprehensive Cancer Network (2021). B-Cell Lymphomas (Version 5.2021), National Comprehensive Cancer Network."},{"key":"ref_42","unstructured":"National Comprehensive Cancer Network (2022). Hodgkin Lymphoma (Version 1.2022), National Comprehensive Cancer Network."},{"key":"ref_43","unstructured":"National Comprehensive Cancer Network (2022). Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Version 1.2022), National Comprehensive Cancer Network."},{"key":"ref_44","unstructured":"National Comprehensive Cancer Network (2022). Multiple Myeloma (Version 4.2022), National Comprehensive Cancer Network."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.beha.2019.101094","article-title":"Will New Agents Impact Survival in AML?","volume":"32","author":"Rowe","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_46","first-page":"38","article-title":"Acute Myeloid Leukemia: A Review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"Rhode Isl. Med. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute Myeloid Leukemia: A Comprehensive Review and 2016 Update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2018.36.15_suppl.1568","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 2006 to 2016: A Systematic Analysis for the Global Burden of Disease Study","volume":"36","author":"Fitzmaurice","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijlh.13135","article-title":"How I Investigate Acute Myeloid Leukemia","volume":"42","author":"Narayanan","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/gcc.22375","article-title":"Improved Minimal Residual Disease Detection by Targeted Quantitative Polymerase Chain Reaction in Nucleophosmin 1 Type a Mutated Acute Myeloid Leukemia: MFC vs. RQ-PCR in MRD Detection in AML","volume":"55","author":"Pettersson","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_52","first-page":"656","article-title":"Gene Expression Profiling of Acute Myeloid Leukemia Samples from Adult Patients with AML-M1 and -M2 through Boutique Microarrays, Real-Time PCR and Droplet Digital PCR","volume":"52","author":"Handschuh","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Grassi, S., Guerrini, F., Ciabatti, E., Puccetti, R., Salehzadeh, S., Metelli, M.R., Di Vita, A., Domenichini, C., Caracciolo, F., and Orciuolo, E. (2020). Digital Droplet PCR Is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients. Cancers, 12.","DOI":"10.3390\/cancers12071738"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.10432","article-title":"Monitoring of Minimal Residual Disease in Adult Acute Myeloid Leukemia Using Peripheral Blood as an Alternative Source to Bone Marrow","volume":"92","author":"Maurillo","year":"2007","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","article-title":"The Kinetics of Reduction of Minimal Residual Disease Impacts on Duration of Response and Survival of Patients with Acute Myeloid Leukemia","volume":"20","author":"Buccisano","year":"2006","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2141.2006.06001.x","article-title":"Development of a Quantitative Real-Time Polymerase Chain Reaction Method for Monitoring CEBPA Mutations in Normal Karyotype Acute Myeloid Leukaemia","volume":"133","author":"Smith","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.beha.2010.06.007","article-title":"The Role of Multiparameter Flow Cytometry for Disease Monitoring in AML","volume":"23","author":"Kern","year":"2010","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/ijlh.12670","article-title":"Minimal Residual Disease in Acute Myelogenous Leukemia","volume":"39","author":"Cruz","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2015.255","article-title":"Peripheral Blood Minimal Residual Disease May Replace Bone Marrow Minimal Residual Disease as an Immunophenotypic Biomarker for Impending Relapse in Acute Myeloid Leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-Generation Sequencing for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients with FLT3-ITD or NPM1 Mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Vonk, C.M., Al Hinai, A.S.A., Hanekamp, D., and Valk, P.J.M. (2021). Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13215431"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/asheducation-2014.1.222","article-title":"Defining Minimal Residual Disease in Acute Myeloid Leukemia: Which Platforms Are Ready for \u201cPrime Time\u201d?","volume":"2014","author":"Grimwade","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.blre.2018.04.008","article-title":"Current Status and Trends in the Diagnostics of AML and MDS","volume":"32","author":"Shumilov","year":"2018","journal-title":"Blood Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.4081\/hr.2020.8957","article-title":"Advancing Leukemia Diagnostics: Role of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia","volume":"12","author":"Haferlach","year":"2020","journal-title":"Hematol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"102977","DOI":"10.1016\/j.critrevonc.2020.102977","article-title":"Current Concepts and Future Directions for Hemato-Oncologic Diagnostics","volume":"151","author":"Flach","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40246-019-0220-8","article-title":"Next-Generation Sequencing in Liquid Biopsy: Cancer Screening and Early Detection","volume":"13","author":"Chen","year":"2019","journal-title":"Hum. Genom."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/bloodadvances.2019001156","article-title":"Targeted Next-Generation Sequencing of Circulating Cell-Free DNA vs Bone Marrow in Patients with Acute Myeloid Leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2018-10-880690","article-title":"Prognostic Impact of Circulating Tumor DNA Status Post\u2013Allogeneic Hematopoietic Stem Cell Transplantation in AML and MDS","volume":"133","author":"Nakamura","year":"2019","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jmoldx.2021.05.001","article-title":"Double Drop-Off Droplet Digital PCR","volume":"23","author":"Rausch","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.pathol.2021.01.004","article-title":"Role of Cell-Free DNA in Haematological Malignancies","volume":"53","author":"Lim","year":"2021","journal-title":"Pathology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.mayocp.2018.04.002","article-title":"Clinical Implications of Clonal Hematopoiesis","volume":"93","author":"Steensma","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood-2016-09-740308","article-title":"Molecular Disease Monitoring Using Circulating Tumor DNA in Myelodysplastic Syndromes","volume":"129","author":"Yeh","year":"2017","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gutierrez-Rodrigues, F., Beerman, I., Groarke, E.M., Patel, B.A., Spitofsky, N., Dillon, L.W., Raffo, D.Q., Hourigan, C.S., Kajigaya, S., and Ferrucci, L. (2021). Utility of Plasma Cell-Free DNA for de Novo Detection and Quantification of Clonal Hematopoiesis. Haematologica, early view.","DOI":"10.3324\/haematol.2021.279230"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO Classification and Diagnostic Criteria for Myeloproliferative Neoplasms: Document Summary and in-Depth Discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia Vera and Essential Thrombocythemia: 2021 Update on Diagnosis, Risk-stratification and Management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/bjh.17087","article-title":"Circulating Cell-Free DNA Improves the Molecular Characterisation of Ph-Negative Myeloproliferative Neoplasms","volume":"192","author":"Gibert","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2354.2005.00513.x","article-title":"A Systematic Literature Review of the Clinical and Epidemiological Burden of Acute Lymphoblastic Leukaemia (ALL)","volume":"14","author":"Redaelli","year":"2005","journal-title":"Eur. J. Cancer Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737159.2017.1377073","article-title":"An Update on PCR Use for Minimal Residual Disease Monitoring in Acute Lymphoblastic Leukemia","volume":"17","author":"Nunes","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized Flow Cytometry for Highly Sensitive MRD Measurements in B-Cell Acute Lymphoblastic Leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kruse, A., Abdel-Azim, N., Kim, H.N., Ruan, Y., Phan, V., Ogana, H., Wang, W., Lee, R., Gang, E.J., and Khazal, S. (2020). Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031054"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2015-07-655159","article-title":"The Predictive Strength of Next-Generation Sequencing MRD Detection for Relapse Compared with Current Methods in Childhood ALL","volume":"126","author":"Kotrova","year":"2015","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/bloodadvances.2021004234","article-title":"Concordance of Peripheral Blood and Bone Marrow Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia","volume":"5","author":"Muffly","year":"2021","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.leu.2402636","article-title":"Minimal Residual Disease Levels in Bone Marrow and Peripheral Blood Are Comparable in Children with T Cell Acute Lymphoblastic Leukemia (ALL), but Not in Precursor-B-ALL","volume":"16","author":"Jacobs","year":"2002","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-009-0698-6","article-title":"Quantification of Free Total Plasma DNA and Minimal Residual Disease Detection in the Plasma of Children with Acute Lymphoblastic Leukemia","volume":"88","author":"Schwarz","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Cheng, S.H., Lau, K.M., Li, C.K., Chan, N.P.H., Ip, R.K.L., Cheng, C.K., Lee, V., Shing, M.M.K., Leung, A.W.K., and Ha, S.Y. (2013). Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069467"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4274\/balkanmedj.galenos.2020.2019.8.25","article-title":"The Impact of Pre-Transplant Cell-Free DNA Levels on Leukemia Relapse and Transplant-Related Complications in Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"37","author":"Yegin","year":"2020","journal-title":"Balk. Med. J."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Camus, V., and Jardin, F. (2021). Cell-Free DNA for the Management of Classical Hodgkin Lymphoma. Pharm. Basel Switz., 14.","DOI":"10.3390\/ph14030207"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000475530","article-title":"Tumor Heterogeneity in Lymphomas: A Different Breed","volume":"85","author":"Federmann","year":"2018","journal-title":"Pathobiology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.beha.2018.07.004","article-title":"Monitoring Clinical Outcomes in Aggressive B-Cell Lymphoma: From Imaging Studies to Circulating Tumor DNA","volume":"31","author":"Melani","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14737159.2017.1319765","article-title":"The Value of Liquid Biopsy in Diagnosis and Monitoring of Diffuse Large B-Cell Lymphoma: Recent Developments and Future Potential","volume":"17","author":"Camus","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.clon.2017.03.008","article-title":"Circulating Cell-Free DNA Utility for the Surveillance of Patients with Treated Diffuse Large B-Cell Lymphoma","volume":"29","author":"Li","year":"2017","journal-title":"Clin. Oncol. R. Coll. Radiol. G. B."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5045\/br.2019.54.2.114","article-title":"Clinical Significance of Cell-Free DNA as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma","volume":"54","author":"Eskandari","year":"2019","journal-title":"Blood Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00277-020-04008-3","article-title":"Plasma Cell-Free DNA Is a Prognostic Biomarker for Survival in Patients with Aggressive Non-Hodgkin Lymphomas","volume":"99","author":"Hur","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"658234","DOI":"10.3389\/fonc.2021.658234","article-title":"Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma","volume":"11","author":"Lv","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12439","article-title":"Detection of Circulating Tumour DNA in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"163","author":"Armand","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive Monitoring of Diffuse Large B-Cell Lymphoma by Immunoglobulin High-Throughput Sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating Tumour DNA and CT Monitoring in Patients with Untreated Diffuse Large B-Cell Lymphoma: A Correlative Biomarker Study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-Generation Sequencing-Based Detection of Circulating Tumour DNA After Allogeneic Stem Cell Transplantation for Lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/pgs-2019-0099","article-title":"Cell-Free DNA and the Monitoring of Lymphoma Treatment","volume":"20","author":"Camus","year":"2019","journal-title":"Pharmacogenomics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00277-017-3043-5","article-title":"Assessment of the Circulating Cell-Free DNA Marker Association with Diagnosis and Prognostic Prediction in Patients with Lymphoma: A Single-Center Experience","volume":"96","author":"Li","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse Large B-Cell Lymphoma Genotyping on the Liquid Biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","article-title":"Mutational Landscape and Tumor Burden Assessed by Cell-Free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study","volume":"27","author":"Nadeu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced Detection of Minimal Residual Disease by Targeted Sequencing of Phased Variants in Circulating Tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct Biological Subtypes and Patterns of Genome Evolution in Lymphoma Revealed by Circulating Tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2019.04.013","article-title":"Cell-Free DNA as a Biomarker in Diffuse Large B-Cell Lymphoma: A Systematic Review","volume":"139","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/CMAR.S242903","article-title":"Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population","volume":"12","author":"Chen","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1080\/10428194.2019.1573998","article-title":"Analysis of Circulating Tumor DNA by Targeted Ultra-Deep Sequencing across Various Non-Hodgkin Lymphoma Subtypes","volume":"60","author":"Shin","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1111\/cas.14176","article-title":"Mutations Found in Cell-free DNAs of Patients with Malignant Lymphoma at Remission Can Derive from Clonal Hematopoiesis","volume":"110","author":"Suehara","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/10428194.2018.1474463","article-title":"Circulating Tumor DNA Assessment in Patients with Diffuse Large B-Cell Lymphoma Following CAR T-Cell Therapy","volume":"60","author":"Hossain","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fonc.2019.00528","article-title":"The Minimal Residual Disease in Non-Hodgkin\u2019s Lymphomas: From the Laboratory to the Clinical Practice","volume":"9","author":"Galimberti","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","article-title":"Advances in the Assessment of Minimal Residual Disease in Mantle Cell Lymphoma","volume":"13","author":"Jung","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2018-99-112573","article-title":"Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma","volume":"132","author":"Lakhotia","year":"2018","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic Molecular Monitoring Reveals That SWI\u2013SNF Mutations Mediate Resistance to Ibrutinib plus Venetoclax in Mantle Cell Lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-Term Follow up of the FL2000 Study Comparing CHVP-Interferon to CHVP-Interferon plus Rituximab in Follicular Lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The Prognostic Value of Clonal Heterogeneity and Quantitative Assessment of Plasma Circulating Clonal IG-VDJ Sequences at Diagnosis in Patients with Follicular Lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total Metabolic Tumor Volume, Circulating Tumor Cells, Cell-Free DNA: Distinct Prognostic Value in Follicular Lymphoma","volume":"2","author":"Dupuis","year":"2018","journal-title":"Blood Adv."},{"key":"ref_122","unstructured":"Jimenez-Ubieto, A.I., Heredia, Y., de la Rosa, J.M., Rodriguez-Izquierdo, A., Rufian, L., Carrillo, J., Sanchez, R., Onecha, E., Wang, C., and Sarandeses, P. (2020, January 5\u20138). Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients. Proceedings of the 62nd ASH Annual Meeting and Exposition, Virtual. 282."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00277-016-2602-5","article-title":"Characteristics and Outcome of Patients with Primary CNS Lymphoma in a \u201cReal-Life\u201d Setting Compared to a Clinical Trial","volume":"95","author":"Zeremski","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cas.13450","article-title":"Clinical Significance of Disease-Specific MYD88 Mutations in Circulating DNA in Primary Central Nervous System Lymphoma","volume":"109","author":"Hattori","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Yoon, S.E., Kim, Y.J., Shim, J.H., Park, D., Cho, J., Ko, Y.H., Park, W.-Y., Mun, Y.-C., Lee, K.E., and Cho, D. (2021). Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. Cancer Res. Treat., Epub ahead of print.","DOI":"10.4143\/crt.2021.752"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/bjh.15674","article-title":"MYD88 p.(L265P) Detection on Cell-Free DNA in Liquid Biopsies of Patients with Primary Central Nervous System Lymphoma","volume":"185","author":"Leguit","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","article-title":"Tumor Cell-Free DNA Detection in CSF for Primary CNS Lymphoma Diagnosis","volume":"7","author":"Rimelen","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1111\/cas.15133","article-title":"Liquid Biopsy of Cerebrospinal Fluid for MYD88 L265P Mutation Is Useful for Diagnosis of Central Nervous System Lymphoma","volume":"112","author":"Yamagishi","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/10428194.2020.1768382","article-title":"Combination of Multicolor Flow Cytometry for Circulating Lymphoma Cells and Tests for the RHOAG17V and IDH2R172 Hot-Spot Mutations in Plasma Cell-Free DNA as Liquid Biopsy for the Diagnosis of Angioimmunoblastic T-Cell Lymphoma","volume":"61","author":"Hayashida","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_130","first-page":"4198","article-title":"Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL","volume":"5","author":"Miljkovic","year":"2021","journal-title":"Blood Adv."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","article-title":"Part II: Hodgkin\u2019s Lymphoma--Diagnosis and Treatment","volume":"5","author":"Diehl","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/10428194.2018.1492123","article-title":"Somatic Mutations of Cell-Free Circulating DNA Detected by Targeted next-Generation Sequencing and Digital Droplet PCR in Classical Hodgkin Lymphoma","volume":"60","author":"Bessi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted Genotyping of Circulating Tumor DNA for Classical Hodgkin Lymphoma Monitoring: A Prospective Study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating Tumor DNA Reveals Genetics, Clonal Evolution, and Residual Disease in Classical Hodgkin Lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and Prognostic Value of Recurrent Exportin 1 Mutations in Tumor and Cell-Free Circulating DNA of Patients with Classical Hodgkin Lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic Lymphocytic Leukemia in the Elderly: Clinico-Biological Features, Outcomes, and Proposal of a Prognostic Model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis from the Randomized GCLLSG CLL8 Trial","volume":"30","author":"Ritgen","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/asheducation.V2012.1.97.3798195","article-title":"A Look into the Future: Can Minimal Residual Disease Guide Therapy and Predict Prognosis in Chronic Lymphocytic Leukemia?","volume":"2012","author":"Ghia","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of Bone Marrow Minimal Residual Disease May Prompt Early Treatment Discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fonc.2019.00689","article-title":"Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?","volume":"9","author":"Raponi","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal Gammopathy of Undetermined Significance (MGUS) Consistently Precedes Multiple Myeloma: A Prospective Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued Improvement in Survival in Multiple Myeloma: Changes in Early Mortality and Outcomes in Older Patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ejh.12925","article-title":"Cell-Free DNA\u2014Minimally Invasive Marker of Hematological Malignancies","volume":"99","author":"Kubaczkova","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"783703","DOI":"10.3389\/fonc.2021.783703","article-title":"Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells","volume":"11","author":"Wong","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of Genomic Evolution and Mutational Profiles in Multiple Myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal Heterogeneity Is a Critical Early Event in the Development of Myeloma and Precedes the Development of Clinical Symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a Model for the Process of Metastasis: Implications for Therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5772\/64124","article-title":"Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma","volume":"5","author":"Zhang","year":"2016","journal-title":"J. Circ. Biomark."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"363ra147","DOI":"10.1126\/scitranslmed.aac7037","article-title":"Genetic Interrogation of Circulating Multiple Myeloma Cells at Single-Cell Resolution","volume":"8","author":"Lohr","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.15003","article-title":"Enumeration and Characterization of Circulating Multiple Myeloma Cells in Patients with Plasma Cell Disorders","volume":"180","author":"Foulk","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","article-title":"Transcriptional Profiling of Circulating Tumor Cells in Multiple Myeloma: A New Model to Understand Disease Dissemination","volume":"34","author":"Simicek","year":"2020","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.1016\/j.clml.2020.06.025","article-title":"Monitoring Plasma Cell Dyscrasias with Cell-Free DNA Analysis","volume":"20","author":"Gavriatopoulou","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.exphem.2015.01.002","article-title":"Quantitative Polymerase Chain Reaction Analysis with Allele-Specific Oligonucleotide Primers for Individual IgH VDJ Regions to Evaluate Tumor Burden in Myeloma Patients","volume":"43","author":"Sata","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2016.161414","article-title":"Monitoring Multiple Myeloma by Next-Generation Sequencing of V(D)J Rearrangements from Circulating Myeloma Cells and Cell-Free Myeloma DNA","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2016.366","article-title":"Circulating Tumour DNA Analysis Demonstrates Spatial Mutational Heterogeneity That Coincides with Disease Relapse in Myeloma","volume":"31","author":"Mithraprabhu","year":"2017","journal-title":"Leukemia"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2016.160564","article-title":"Monitoring Multiple Myeloma by Quantification of Recurrent Mutations in Serum","volume":"102","author":"Rustad","year":"2017","journal-title":"Haematologica"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.3324\/haematol.2017.184358","article-title":"Circulating Tumor DNA as a Liquid Biopsy in Plasma Cell Dyscrasias","volume":"103","author":"Gerber","year":"2018","journal-title":"Haematologica"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jmoldx.2018.07.006","article-title":"Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA","volume":"20","author":"Biancon","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1038\/ncomms15086","article-title":"Circulating Tumour DNA Sequence Analysis as an Alternative to Multiple Myeloma Bone Marrow Aspirates","volume":"8","author":"Kis","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.13358","article-title":"Dynamics of Tumor-specific CfDNA in Response to Therapy in Multiple Myeloma Patients","volume":"104","author":"Vrabel","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring Tumour Burden and Therapeutic Response through Analysis of Circulating Tumour DNA and Extracellular RNA in Multiple Myeloma Patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/ejh.13541","article-title":"Monitoring Treatment Response and Disease Progression in Myeloma with Circulating Cell-free DNA","volume":"106","author":"Deshpande","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1097\/HS9.0000000000000402","article-title":"Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma","volume":"4","author":"Manzoni","year":"2020","journal-title":"HemaSphere"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminhematol.2018.03.002","article-title":"Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma","volume":"55","author":"Pugh","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by Deep Sequencing from Circulating Tumor DNA Does Not Correlate with Results Obtained in the Bone Marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16440","article-title":"The Utility of Non-invasive Liquid Biopsy for Mutational Analysis and Minimal Residual Disease Assessment in Extramedullary Multiple Myeloma","volume":"189","author":"Long","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-Exome Sequencing of Cell-Free DNA and Circulating Tumor Cells in Multiple Myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","article-title":"Genomic Discovery and Clonal Tracking in Multiple Myeloma by Cell-Free DNA Sequencing","volume":"32","author":"Guo","year":"2018","journal-title":"Leukemia"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"101146","DOI":"10.1016\/j.beha.2020.101146","article-title":"Tracking Myeloma Tumor DNA in Peripheral Blood","volume":"33","author":"Waldschmidt","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"90610","DOI":"10.18632\/oncotarget.21595","article-title":"Circulating Tumour DNA Analysis in Multiple Myeloma","volume":"8","author":"Mithraprabhu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Medina Diaz, I., Nocon, A., Mehnert, D.H., Fredebohm, J., Diehl, F., and Holtrup, F. (2016). Performance of Streck CfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166354"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14737159.2019.1568873","article-title":"Technical Considerations for Circulating Tumor DNA Detection in Oncology","volume":"19","author":"Franczak","year":"2019","journal-title":"Expert Rev. Mol. Diagn."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:31:40Z","timestamp":1760135500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":175,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14051310"],"URL":"https:\/\/doi.org\/10.3390\/cancers14051310","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202201.0366.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]}}}